Wave Life Sciences surged over 120% after Phase 1 data showed WVE-007 produced meaningful visceral and total fat loss, lean-mass gains, and durable biomarker effects, including strong Activin E suppression through Day 85. The drug was well tolerated with no severe adverse events, fuelling trader optimism for a potential blockbuster.